Publication Name	World Journal of Virology
Manuscript ID	70181
Country	Greece

Received	2021-07-25 20:06
Peer-Review Started	2021-07-25 20:11
To Make the First Decision
Return for Revision	2021-11-11 09:07
Revised	2021-11-29 08:57
Second Decision	2022-02-08 05:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-02-10 16:22
Articles in Press	2022-02-10 16:22
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-01-17 03:26
Typeset the Manuscript	2022-03-21 01:52
Publish the Manuscript Online	2022-03-22 04:46

ISSN	2220-3249 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Virology
Manuscript Type	Opinion Review
Article Title	Rifampicin for COVID-19
Manuscript Source	Unsolicited Manuscript
All Author List	George D Panayiotakopoulos and Dimitrios T Papadimitriou
ORCID	Author(s) ORCID Number George D Panayiotakopoulos http://orcid.org/0000-0002-9303-8854 Dimitrios T Papadimitriou http://orcid.org/0000-0002-6083-3560
Funding Agency and Grant Number
Corresponding Author	Dimitrios T Papadimitriou, MD, MSc, PhD, Academic Fellow, Director, Department of Pediatric, Adolescent Endocrinology & Diabetes, Athens Medical Center, 58 av. Kifisias , Marousi 15125, Greece. info@pedoendo.net
Key Words	COVID-19; SARS-CoV-2; Rifampicin; Antiviral activity; RNA polymerase
Core Tip	Rifampicin may prove pharmacologically effective, supplying a possible and cost-effective solution to the global battle against severe acute respiratory syndrome coronavirus 2, not only for treatment but also for chemoprophylaxis of those at higher risk. It is also possible to administer rifampicin by nebulization. The publications describing the in vitro mechanisms and providing proof of clinical efficacy of rifampicin against RNA viruses with their own RNA polymerase have emerged since 1969-1971. Recent in silico studies using a computer-aided approach, found rifampicin among the most promising existing drugs that can be repurposed for the treatment of coronavirus disease-2019.
Publish Date	2022-03-22 04:46
Citation	Panayiotakopoulos GD, Papadimitriou DT. Rifampicin for COVID-19. World J Virol 2022; 11(2): 90-97
URL	https://www.wjgnet.com/2220-3249/full/v11/i2/90.htm
DOI	https://dx.doi.org/10.5501/wjv.v11.i2.90

Full Article (PDF)	WJV-11-90.pdf
Full Article (Word)	WJV-11-90.docx
Manuscript File	70181_Auto_Edited.docx
Answering Reviewers	70181-Answering reviewers.pdf
Audio Core Tip	70181-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	70181-Conflict-of-interest statement.pdf
Copyright License Agreement	70181-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	70181-Language certificate.pdf
Peer-review Report	70181-Peer-review(s).pdf
Scientific Editor Work List	70181-Scientific editor work list.pdf